SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust (SLV) is experiencing a historic surge, propelled by strong physical demand, notably from China, alongside rising industrial applications in AI and electric vehicles. This rally is generating intense community discussion, with many anticipating a significant short squeeze and the end of prolonged price suppression. However, others remain cautious, debating if the rapid ascent signifies a true repricing or an overextended, speculative move.

A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.

A SPAC III Acquisition Corp. - Ordinary Shares - Class A

Alpha Capital Acquisition Co - Ordinary Shares - Class A

ASPC is currently experiencing extreme volatility and frequent trading halts, fueling a heated debate among investors. Bulls are driving a potential short squeeze, pointing to its low float and high borrow rates, while bears caution against a pump-and-dump, often referencing its nature as a Chinese SPAC. The community is actively discussing whether this momentum will lead to further parabolic gains or a rapid reversal, drawing parallels to other recent volatile low-float plays.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is trending due to its specialized AI chips, particularly the energy-efficient Gemini-II APU, which is gaining traction for edge computing in defense and drone applications. The stock is a focal point of intense community debate, with bulls highlighting recent academic validation and potential government contracts as key catalysts, while bears point to commercial struggles and fundamental technology concerns, fueling significant market volatility.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending amid China's recent sanctions, a move widely interpreted by the community as validation of its strategic importance and a bullish signal for a U.S. defense contractor. This, alongside the impending U.S. ban on foreign-made drones and significant anticipated defense spending, is fueling community discussion around RCAT's readiness for substantial government contracts and market share expansion.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is gaining significant attention, driven by anticipation for its upcoming CES 2026 showcase and the positive impact of its Marigold acquisition, alongside robust financial outlooks. The community widely regards it as an undervalued AI-powered marketing leader, expecting a substantial re-rating fueled by its innovative Athena platform and strategic first-party data capabilities.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending amid an explosive global surge in silver prices, significantly higher in Asian markets, driven by severe supply deficits and robust industrial demand. Despite widespread frustration among investors over AG's stock lagging the metal's performance, the community firmly anticipates an inevitable, substantial catch-up rally for this pure-play silver miner.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending after announcing preliminary Phase 3 trial results for its GLSI-100 immunotherapy, showing an estimated 80% reduction in breast cancer recurrence within an open-label arm. This positive clinical update, coupled with reports of consistent insider buying and an extremely high cost-to-borrow rate, has ignited widespread community discussion about a potential short squeeze. Many investors hold strong conviction in GLSI's long-term valuation and significant strategic partnership or buyout potential within the biotech sector.

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Universe Pharmaceuticals INC

Universe Pharmaceuticals (UPC) is trending sharply due to its extremely low float, fueling speculation of a massive short squeeze and rapid price movements including trading halts. The community is actively debating its potential for significant upside, with some highlighting its strong cash position, while others warn of a pump-and-dump in the volatile small-cap 'China floater' sector. This polarized sentiment is driving intense conversation around its dramatic market activity.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is experiencing significant buzz following FDA approval of YARTEMLEA, establishing it as the first and only approved therapy for a life-threatening transplant complication. The community is highly optimistic about the company's de-risked financial standing, supported by a substantial licensing deal, anticipating strong revenue potential and further insights from an upcoming conference call. Many believe the stock remains undervalued, eyeing significant long-term growth and potential for a short squeeze.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

Starfighters Space Inc. ($FJET) is experiencing extreme volatility and trending due to an exceptionally high borrow rate, sparking a heated short squeeze discussion. While proponents highlight its low float and unique Mach 2 aerospace technology with potential government contracts, critics point to significant dilution, lack of revenue, and classify it as a speculative 'pump and dump' within the currently active space sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight ratings firms that are currently covering the stock...

Sagimet Biosciences (NASDAQ:SGMT) Stock Price Up 5.4% - Still a Buy?

Sagimet Biosciences (NASDAQ:SGMT) Trading Up 5.4% - Time to Buy...

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment Ascletis Announces...

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine brokerages that are covering the company, Marketbeat reports. One...

Sagimet Biosciences (NASDAQ:SGMT) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Sagimet Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday...

Insider Selling: Sagimet Biosciences (NASDAQ:SGMT) Chairman Sells 37,688 Shares of Stock

Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) Chairman George Kemble sold 37,688 shares of the company's stock in a transaction on Thursday, November 20th. The shares were sold at an...

George Kemble Sells 37,688 Shares of Sagimet Biosciences (NASDAQ:SGMT) Stock

Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) Chairman George Kemble sold 37,688 shares of the firm's stock in a transaction that occurred on Thursday, November 20th. The stock was sold at...

Sagimet Biosciences (NASDAQ:SGMT) Releases Earnings Results, Beats Expectations By $0.01 EPS

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts...

Citizens Jmp Forecasts Strong Price Appreciation for Sagimet Biosciences (NASDAQ:SGMT) Stock

Citizens Jmp upped their price target on Sagimet Biosciences from $33.00 to $35.00 and gave the stock a "market outperform" rating in a report on Friday...

Sagimet Biosciences (NASDAQ:SGMT) Lowered to Hold Rating by Zacks Research

Zacks Research downgraded shares of Sagimet Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday...

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Current Price	$5.94
Prev Close	$6.06
Open	$6.04
Dividend Yield	0.00%
50-Day Moving Average	$7.23
Beta	0.00
Avg. Volume	480,585.05
PE Ratio	-3.39

52-Week High	$11.41
52-Week Low	$1.73
Market Capitalization	$187.87M
EPS (Annual)	-$1.45
Price to Book	1.65
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SGMT
Sagimet Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGMT News

SGMTSagimet Biosciences Inc